Epoxyvibsanin B

Details Epoxyvibsanin B Epoxyvibsanin B

2002-01-25

2002-10-08

Trinh, Ba K. (Department: 1625)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C549S546000

Reexamination Certificate

active

06462078

ABSTRACT:

BACKGROUND OF THE INVENTION
Interleukin-12 (IL-12) is a pivotal cytokine that mediates IL-12 receptors for producing proinflammatory cytokines, or promotes specific lymphocyte responses. One of its key roles is to promote type 1 T helper cell (Th1) responses and, hence, cell-mediated immunity. Overproduction of IL-12 will cause excessive Th1 responses, which may result in inflammatory disorders, such as autoimmune diseases. Gately et al. 1998,
Annu Rev lmmunol.
16, 495. IL-12 is therefore an ideal target for pharmacological intervention in the therapy of inflammatory diseases caused by excessive proliferation of Th1 cells. Trembleau et al. 1995;
Immunol. Today
16, 383, and Adorini et al. 1997;
Chem. Immunol.
68, 175. Overproduction of IL-12 and the resultant Th1 type immune responses can be suppressed with several pharmacological approaches including modulation of intracellular cyclic AMP levels, and inhibition of glucocorticoids and nuclear factor-kappaB. Hasko et al. 1999,
Br. J. Pharmacol
127, 1295. It is desirable to identify a new compound for treatment of IL-12 overproduction-related disorders.
SUMMARY OF THE INVENTION
This invention is based on the identification of a new compound from a library of plant extracts, which were screened for their abilities to inhibit IL-12 production.
An aspect of this invention relates to the compound, epoxyvibsanin B, of the formula:
This compound can be either synthesized from organic chemicals or isolated from a natural source, e.g.,
Caprifoliaceae vibrunum Awabuki.
Another aspect of this present invention relates to a method of treating an IL-12 overproduction-related disorder with epoxyvibsanin B. The method includes administering to a subject in need thereof an effective amount of this compound.
Epoxyvibsanin B is formulated into a pharmaceutical composition before it is administered to a subject in need of treatment of an IL-12 overproduction-related disorder, which includes inflammatory (both acute and chronic) such as autoimmune diseases. Thus, also within the scope of the present invention is a pharmaceutical composition that contains an effective amount of epoxyvibsanin B and a pharmaceutically acceptable carrier for use in treatment of IL-12 overproduction-related disorders. The present invention also encompasses the use of epoxyvibsanin B for the manufacture of a medicament for treatment of the above-mentioned disorders.
Other advantages or features of the present invention will be apparent form the following detailed description thereof.


REFERENCES:
Yoshiyasu Fukuyama, et al. Chemical Conversion of Vibsanin C to Vibsanin E and Structure of 3-Hydroxyvibsanin E fromViburnum awabuki.J. Nat. Prod. 62:337-339, 1999.
Kazuyoshi Kawazu. Isolation of Vibsanins A, B, C, D, E, and F fromViburnum odoratissimum.Agric. Biol. Chem. 44(6):1367-1372, 1980.
Yoshiyasu Fukuyama, et al. Abolute Structure of Vibsanins B and C, and Their Chemical Correlation. Tetrahedron Letters 38(8):1435-1438, 1997.
Keiichi Fukuyama, et al. Structure and Absolute Configuration of Visanine E isolated from Leaves ofViburnum odoratissimumKer. J.C.S. Perkin III, pp. 1701-1703, 1980.
Miwa Kubo, et al. Vibsane-type Diterpenes from TaiwaneseViburnum odoratissimum.Chem. Pharm. Bull. 49(2):242-245, 2001.

Affiliated with

Also associated with

Rating

Epoxyvibsanin B does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Epoxyvibsanin B, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Epoxyvibsanin B will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2964553